CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 50 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04602806
NCT04602806N/AActive

TRACK-TBI Precision Medicine Phase 2-Option I

University of California, San Francisco·observational·Posted Oct 26, 2020·Updated Apr 13, 2025

In Brief

An observational study for Traumatic Brain Injury. Active but no longer recruiting, targeting 50 participants across 5 sites.

Detailed Summary

This study is being conducted to validate early and ultra-early blood-based and novel imaging biomarkers of Diffuse Axonal Injury (DAI), Microvascular Injury (MVI), and neuroinflammation that may serve as predictive and pharmacodynamic biomarkers in a new cohort of moderate-severe TRACK-TBI subjects. The study team will enroll a cohort of moderate to severe TBI subjects (N=50), stratified according to VA/DoD criteria for these injury severities through the existing TRACK-TBI network sites to obtain novel advanced neuroimaging and more frequent biomarker sampling. Subjects will be assessed over 3 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/AActive
2021202220232024202520262027202820292030
First PostedOct 26, 2020
Enrollment StartJun 1, 2021
Primary CompletionNov 11, 2022
Study CompletionApr 9, 2030
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.7 years ago